PTO/SB/21 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

11

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission (including this transmittal form)

Application Number	10/660,256
Filing Date	September 11, 2003
First Named Inventor	Arthur Ramazanov
Art Unit	
Examiner Name	
Attorney Docket Number	04287/100M315-US1

	ENCLOSURES (Check all that apply)					
X Fee Transn	nittal Form (1 page)	Drawing(s)	After Allowance Communication to Group			
Fee A	Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences			
Amendmen	nt/Reply	Petition	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)			
After	Final	Petition to Convert to a Provisional Application	Proprietary Information			
Affida	avits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter			
Extension of	of Time Request	Terminal Disclaimer	Other Enclosure(s) (please identify below):			
Express Ab	andonment Request	Request for Refund	Certificate of Express Mailing (1 page)			
x Information	Disclosure Statement	CD, Number of CD(s)				
Certified Co	opy of Priority s)					
	to Missing Parts/ Application	Remarks				
Resp	onse to Missing Parts	The Information Disclosure States Disclosure Statement (4 pages),				
undei undei	r 37 CFR 1.52 or 1.53	54 documents	, commercial designation			
	SIGNATI	JRE OF APPLICANT, ATTORNEY, OF	RAGENT			
Firm or Individual name	or S Peter Ludwig - 25 351					
Signature)/Val	Tyn				
Date	December 2, 2003					

Express Mail Label No.	Dated:



Attorney Docket No.: 04287/100M315-US1

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. in an envelope addressed to:

20 - 1 1 1 0 6 1 4 1 عنى

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on December 2, 2003

Date

Signature


Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal form (1 page)
Fee Transmittal for FY 2004 (1 page)
Information Disclosure Statement (4 pages)
Form PTO SB/08 (4 pages)
54 documents
Return receipt postcard

Use in lieu of PTO/SB/17 (08-03) (Form updated to reflect FY 2004 fees effective 10/1/03)

FEE TRANSMITTAL		Complete if Known				
FEE IKANSWIIIIAL		Applic	cation	Numbe	er 10/660,256	
for FY 2004		Filing	Date		September 11, 2003	
		First Named Inventor Arthur Ramazanov		ntor Arthur Ramazanov		
Effective 10/01/2003, Patent fees are subject to annual revision.		Exam	iner Na	ame		
X Applicant claims small entity status. See 37 CFR 1.27		Art Ur	nit			
TOTAL AMOUNT OF PAYMENT (\$) 0.00		Attorn	ey Do	cket No	o. 04287/100M315-US1	
METHOD OF PAYMENT (check all that apply)				FEE	E CALCULATION (continued)	
Check Credit Money Other X None	3 /	ADDITIO	ONAL			
Card Order Card	3. /	100111	JIIAL			
Deposit Account:	Large	e Entity	Smáli	Entity		
Deposit Account . 04-0100	Fee	Fee	Fee	Fee	Fee Description	
Number	Code	(\$)	Code	(\$)	Fee Paid	
Deposit Account Darby & Darby P.C.	1051	130	2051	65	Surcharge – late filing fee or oath	
Name The Director is authorized to: (check all that apply)	1052	50	2052	25	Surcharge – late provisional filing fee or cover sheet.	
Charge fee(s) indicated below X Credit any overpayments	1053	130	1053	130	Non-English specification	
Charge any additional fee(s) during the pendency of this	1812	2,520	1812		For filing a request for ex parte reexamination	
аррисации	1804	920*	1804	920*	Requesting publication of SIR prior to	
Charge fee(s) indicated below, except for the filing fee					Examiner action Requesting publication of SIR after	
to the above-identified deposit account.	1805	-	1805		Examiner action	
FEE CALCULATION	1251 1252	110 420	2251 2252	55 210	Extension for reply within first month Extension for reply within second month	
1. BASIC FILING FEE Large Entity Small Entity	1252	950	2252	475	Extension for reply within third month	
Fee Fee Fee Fee <u>Fee Description</u> Fee Paid	1254	1,480	2254	740	Extension for reply within fourth month	
Code (\$) Code (\$) 1001 770 2001 385 Utility filing fee	1255	2,010	2255	1.005	Extension for reply within fifth month	
1002 340 2002 170 Design filing fee	1401	330	2401		Notice of Appeal	
1003 530 2003 265 Plant filing fee	1402	330	2402	165	Filing a brief in support of an appeal	
1004 770 2004 385 Reissue filing fee	1403		2403	145	Request for oral hearing	
1005 160 2005 80 Provisional filing fee	1451 1452	1,510 110	1451 2452	1,510 55	Petition to institute a public use proceeding Petition to revive – unavoidable	
SUBTOTAL (1) (\$) 0.00	1453		2453	665	Petition to revive - unintentional	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501	1,330	2501	665	Utility issue fee (or reissue)	
Extra Fee from Claims below Fee Paid	1502	480	2502	240	Design issue fee	
Total Claims -20** = x =	1503	640	2503	320	Plant issue fee	
Independent -3** = x = x	1460	130	1460	130	Petitions to the Commissioner	
Multiple Dependent = 0.00	1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
Large Entity Small Entity	1806	180	1806	180	Submission of Information Disclosure Stmt	
Fee Fee Fee Fee Code (\$) Fee Description	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1202 18 2202 9 Claims in excess of 20	1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1201 86 2201 43 Independent claims in excess of 3	1810	770	2810	385	For each additional invention to be	
1203 290 2203 145 Multiple dependent claim, if not paid 1204 86 2204 43 ** Reissue independent claims	1801	770	2801	385	examined (37CFR 1.129(b)) Request for Continued Examination (RCE)	
over original patent	1802		1802	900	Request for expedited examination	
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent		fee (spe	l		of a design application	
SUBTOTAL (2) (\$) 0.00		uced by I	• •	ling Fee	e Paid SUBTOTAL (3) (\$) 0.00	
**or number previously paid, if greater; For Reissues, see above		accu by t		g i ee	0.00 (a) (b) (c)	
SUBMITTED BY					(Complete (if applicable))	
Name (Print/Type) S. Feter Ludwig		tration No ey/Agent		,351	Telephone (212) 527-7770	
Signature	LARION	<u>ラッペgent</u> フ		-	Date December 2, 2003	
() () () () () () () () () ()	-	•			December 2, 2003	
Express Mail Label No.			Dat	ed.		
Express Ividii Laber Ivo.			Ual	eu		



PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "Express Mail Post Office to Addressee" service.

Name (Print)

Signature

Customer No.: 07278

Dkt. No. 04287/100M315-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Arthur Ramazanov and Zakir Ramazanov

Serial No.:

10/660,256

Art Unit:

Confirmation No.:

Filed:

September 11, 2003

For:

A NOVEL COMPOSITION FOR THE TREATMENT OF OBESITY AND

EFFECTIVE FAT LOSS PROMOTION

December 2, 2003

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

{W:\04287\100M315-US1\00093422.DOC *04287100M315-US1* }

- 1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed: (Check one of the boxes A-D)
 - [X]A. Within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.
 - [] B. before the mailing date of a first office action on the merits, or a first office action after filing a request for continued examination.
 - [] C. after (A) and (B) above, but before the mailing date of a final rejection, a notice of allowance, or any other action that closes prosecution, and Applicants have made the necessary statement in box "i" below or paid the necessary fee in box "ii" below.

(check one of the boxes "i" and "ii" below:)

- [] i. Counsel states that, upon information and belief, each item of information listed herein was either (a) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
- [] ii. A check for the fee set forth in 1. 17(p), presently believed to be \$180, is enclosed.
- [] D. after (A), (B) and (C) above, but before payment of the issue fee: Counsel states that, upon information and belief, each item of information listed herein was either (i) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the IDS; or (ii) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
 - [] i. A check for the fee set forth in 1.17 (p), presently believed to be \$180, is enclosed.
- 2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for

consideration by t	ne office, either incorporated into this IDS or as an attachment
•	·
. ,	each document listed is attached, except as explained below.
	s A and/or B and fill in blanks, if appropriate.)
[] A.	Document(s) is (are) deemed substantially cumulative to document(s) , and, in accordance with
	1.98(c), only a copy of each of the latter documents is enclosed.
[] B.	Certain documents were previously cited by or submitted to the
	Office in the following prior applications, which are relied upon
	under 35 U.S.C. 120:
	[SERIAL NO. & FILING DATE].
	[00] [00]
Applicant Identifies	these documents by attaching hereto copies of the forms PTO-
892 and PTO- 144	9 from the files of the prior application(s) or a fresh PTO- 1449
listing these docum	nents, and request that they be considered and made of record in
accordance with 1	.98(d). Per 37 CFR 1.98(d), copies of these documents need not
be filed in this appl	ication.
[X] 3. Docu	ment No. <u>46</u> is not in the English language. In accordance with
1.98(c), Applicant	states:
[X]	An English translation of each document (or of the pertinent
	portions thereof), or a copy of each corresponding English-
n	language patent or application is enclosed.
[]	A concise explanation of the relevance of document(s) is found in the attached search report (see MPEP § 609 A(3)x).
[]	A concise explanation of the relevance of document(s)
	is set forth as follows: [Insert concise explanation
	of relevance]
[]	A concise explanation of the relevance of document(s)
f:	can be found on pages of the specification.
[]	A concise explanation of document(s) can be found on

the attached sheet.

- [X] 4. No explanation of relevance is necessary for documents in the English language (see MPEP § 609 A(3)).
- [] 5. Other information being provided for the examiner's consideration follows:
- 6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless other-wise indicated, the date of publication indicated for an item is taken from the face of' the item and Applicant reserves the right to prove that the date of publication is in fact different.

CROSS REFERENCE UNDER 37 C.F.R. §1.78 TO RELATED APPLICATIONS

Pursuant to 37 C.F.R. § 1.78, Applicant notes that the above-identified patent application may be related to the following U.S. Patent Applications:

(1) U.S. Patent Application Serial No _____, filed _____. Early and favorable consideration is earnestly solicited.

Respectfully submitted,

S. Peter Ludwig

Registration No. 25,351 Attorney for Applicant(s)

DARBY & DARBY P.C. 805 Third Avenue New York, N.Y. 10022 (212) 527-7700



PTO/SB/08a/b (05-03)
Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Sub	estitute for form 1449/PTO				Complete if Known
	INFORMATION DISCLOSURE STATEMENT BY APPLICAN (use as many sheets as necessary)		Application Number	US 10/660,256	
l IN		SCLOSURE	Filing Date	Sept. 11, 2003	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Ramazanov et al.
				Art Unit	
	(use as many sho	eets as	necessary)	Examiner Name	
Sheet	1	of	4	Attorney Docket Number	04287/100M315-US1

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1.	4,451,465	05-29-1984	White et al.			
,,,,,,	2.	4,772,631	09-20-1988	Holloway et al.			
	3.	4,977,148	12-11-1990	Holloway et al.			
	4.	4,999,377	03-12-1991	Caulkett et al.			
	5.	5,626,849	05-06-1997	Hastings et al.			
	6.	5,783,603	07-21-1998	Majeed et al.			
	7.	5,804,596	09-08-1998	Majeed et al.			
	8.	6,340,482	01-22-2002	Jones			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	f°

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	9.	Brasaemle et al., (1997) "Post-translational Regulation of Perilipin Expression", <i>The Journal of Biological Chemistry</i> , 272:9378-9387	
	10.	Brasaemle et al. (2000) "Perilipin A Increases Triacylglycerol Storage by Decreasing the Rate of Triacylglycerol Hydrolysis", <i>The Journal of Biological Chemistry</i> , 275:38486-38493	
	11.	Chaudhry and Granneman (1999) "Differential regulation of functional responses by β-adrenergic receptor subtypes in brown adipocytes", <i>Am. J. Physiol.</i> , 277:R147-R153	
	12.	Clifford et al., (1998) "Dephosphorylation of perilipin by protein phosphatases present in rat adipocytes", <i>FEBS Letters</i> , 435:125-129	
	13.	Clifford et al., (2000) "Translocation of Hormone-sensitive Lipase and Perilipin upon Lipolytic Stimulation of Rat Adipocytes", <i>The Journal of Biological Chemistry</i> , 275:5011-5015	

{W:\042	Date	
87\100	Considered	

PTO/SB/08a/b (05-03)
Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Panerwork and John Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitu	Substitute for form 1449/PTO		Complete if Known		
Substitu	te 101 101111 1440/1 10			Application Number	US 10/660,256
INF	ORMATIO	N DISC	LOSURE	Filing Date	Sept. 11, 2003
STATEMENT BY APPLICANT				First Named Inventor	Ramazanov et al.
				Art Unit	
	(use as many si	heets as nec	essary)	Examiner Name	
Sheet	2	of	4	Attorney Docket Number	04287/100M315-US1
Oncol				, , , , , , , , , , , , , , , , , , , ,	042877100101313-031

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	14.	Geodakyan et al., (1992) "High-performance liquid chromatographic method for determination of mangiferin, likviritin and dihydroquercetin in rat plasma and urine", <i>J. of Chromatography</i> , 577:371-375	
	15.	Greenberg et al. (1991) "Perilipin, a Major Hormonally Regulated Adipocyte-specific Phosphoprotein Associated with the Periphery of Lipid Storage Droplets", <i>The Journal of Biological Chemistry</i> , 266:11341-11346	
	16.	Greenberg et al., (1993) "Isolation of cDNAs for perilipins A and B: Sequence and expression of lipid droplet-associated proteins of adipocytes", <i>Proc. Natl. Acad. Sci. USA</i> , 90:12035-12039	
	17.	Han et al., (1998) "Norepinephrine-Augmenting Lipolytic Effectors from Astilbe thunbergii Rhizomes", J. Nat. Prod., 61:1006-1011	
	18.	Haraguchi et al., (1996) "Inhibition of aldose reductase by dihydrofavonols in Engelhardtia chrysolepis and effects on other enzymes", Experientia, 52: 564-567	
	19.	Haraguchi et al., (1996) "Protection against Oxidative Damage by Dihydroflavonols in Engelhardtia chrysolepis", Biosci. Biotech. Biochem. 60:945-948	
	20.	Heymsfield et al., (1998) "Garcinia cambogia (Hydroxycitric Acid) as a Potential Antiobesity Agent: A Randomized Controlled Trial", JAMA, 280:1596-1600	
	21.	Holm et al., (2000) "Molecular Mechanisms Regulating Hormone-Sensitive Lipase and Liposlysis", <i>Annu. Rev. Nutr.</i> , 20:365-393	
	22.	Igarashi et al., (1996) "Effect of Astilbin in Tea Processed from Leaves of Engelhardtia chrysolepis on the Serum and Liver Lipid Concentrations and on the Erythrocyte and Liver Antioxidative Enzyme Activities of Rats", Biosci. Biotech. Biochem., 60:513-515	
	23.	Kellner-Weibel et al., (2001) "Evidence that newly synthesized esterified cholesterol is deposited in existing cytoplasmic lipid inclusions", <i>Journal of Lipid Research</i> , 42:768-777	
	24.	Leonhardt et al., (2002) "Hydroxycitrate Has Long-Term Effects on Feeding Behavior, Body Weight Regain and Metabolism after Body Weight Loss in Male Rats", <i>J. Nutr.</i> , 132:1977-1982	
	25.	Londos et al., (1995) "Perilipin: unique proteins associated with intracellular neutral lipid droplets in adipocytes and steroidogenic cells", <i>Biochem. Society Transactions</i> , 23:611-615	
	26.	Martinez-Botas et al., (2000) "Absence of perilipin results in leanness and reverses obesity in Lepr ^{db/db} mice", <i>Nature Genetics</i> , 26:474-479	
	27.	Mauriege et al., (1999) "Regional and gender variations in adipose tissue lipolysis in response to weight loss", <i>J. of Lipid Research</i> , 40:1559-1571	
	28.	Miyase et al., (1996) "Araliasaponins XII-XVIII, triterpene saponins from the roots of Aralia chinensis", <i>Phytochemistry</i> 42:1123-1130	

{W:\042	Date	
87\100	 Considered	



PTO/SB/08a/b (05-03)
Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** US 10/660,256 **INFORMATION DISCLOSURE** Sept. 11, 2003 Filing Date First Named Inventor STATEMENT BY APPLICANT Ramazanov et al. Art Unit (use as many sheets as necessary) Examiner Name Attorney Docket Number of Sheet 3 04287/100M315-US1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	29.	Miyase et al., (1996) "Araliasaponins I-Xi, triterpene saponins from the roots of Aralia decaisneana", <i>Phytochemistry</i> , 41:1411-1418	
	30.	Morimoto et al., (1997) "Norepinephrine-induced Lipolysis in Rat Fat Cells from Visceral and Subcutaneous Sites: Role of Hormone-sensitive Lipase and Lipid Droplets", <i>J. of Lipid Research</i> , 38:132-138	
	31.	Morimoto et al., (2000) "Mechanism of the stimulatory action of okadaic acid on lipolysis in rat fat cells", <i>J. of Lipid Research</i> , 41:199-204	
	32.	Morimoto et al., (2000) "Substrate-Dependent Lipolysis Induced by Isoproterenol", Biochem and Biophys Res Comm, 274:631-634	
	33.	Morimoto et al., (2001) "Relationships between lipolysis induced by various lipolytic agents and hormone-sensitive lipase in rat fat cells", <i>J. of Lipid Research</i> , 42:120-127	
	34.	Muls et al., (2001) "The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study", <i>International Journal of Obesity</i> , 25:1713-1721	
	35.	Murphy et al., (2000) "New insights into the mechanisms of lipid-body biogenesis in plants and other oganisms", <i>Biochemical Society Transactions</i> , 28:710-711	
	36.	Osterlund T. (2001) "Structure-function relationships of hormone-sensitive lipase", Eur. J. Biochem., 268:1899-1907	-
	37.	Sakai et al., (1994) "Oleanolic acid saponins from root bark of Aralia elata", Phytochemistry, 35:1319-1324	
	38.	Satoh et al., (1994) "Oleanolic acid saponins from root-bark of Aralia elata", Phytochemistry, 36:147-152	
	39.	Sedykh et al., (1986) "The Influence of the Aralia Mandshurica Tincture, Aminalon or Their Combination for Memorization of Texts", New Medicinal Preparation from Plants of Siberia and the Far East, p. 132	
	40.	Servetnick et al., (1995) "Perilipins Are Associated with Cholesteryl Ester Droplets in Seroidogenic Adrenal Cortical and Leydig Cells", <i>The Journal of Biological Chem</i> , 270:16970-16973	
	41.	Snow J.M. (1995) "Coleus forskohlii Willd. (Lamiaceae)", The Protocol Journal of Botanical Medicine, pg. 39-42	
	42.	Souquet et al., (2000) "Phenolic Composition of Grape Stems", J. Agric. Food Chem., 48:1076-1080	
	43.	Souza et al., (1998) "Overexpression of Perilipin A and B Blocks the Ability of Tumor Necrosis Factor <i>α</i> to Increase Lipolysis in 3T3-L1 Adipocytes", <i>The Journal of Biological Chemistry</i> , 273:24665-24669	

	· · · · · · · · · · · · · · · · · · ·
{W:\042	Date
87\100	Considered
(87/100 I	0



PTO/SB/08a/b (05-03)
Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
Suc	suitate for form 1440/110			Application Number	US 10/660,256	
11	IFORMATION	I DI	SCLOSURE	Filing Date	Sept. 11, 2003	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Ramazanov et al.	
01 /(122.11.2.71.2.71				Art Unit		
(use as many sheets as necessary)				Examiner Name		
Sheet	4	of	4	Attorney Docket Number	04287/100M315-US1	

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	44.	Tansey et al., (2001) "Perilipin ablation results in a lean mouse with aberrant			
		adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity", PNAS, 98:6494-6499			
	45.	Theriault et al., (2000) "Modulation of hepatic lipoprotein synthesis and secretion by taxifolin, a plant flavonoid", <i>Journal of Lipid Research</i> , 41:1969-1979			
	46.	Tiukavkina et al., (1997) "Dihydroquercetin - a new antioxidant and biologically active food additive", <i>Vopr Pitan</i> , 6:12-15			
	47.	Wang et al., (1994) "Chemical analysis of main medicinal species of genus Aralia", CHung Kuo Chung Yao Tsa Chih, 19:6-8			
	48.	Yamamoto et al., (2000) "Anti-obesity effects of lipase inhibitor CT-II, an extract from edible herbs, Nomame Herba, on rats fed a high-fat diet", <i>International Journal of Obesity</i> , 24:758-764			
,	49.	Yoshikawa et al., (1995) "Medicinal foodstuffs. I. Hypoglycemic constituents from a garnish foodstuff "taranome," the young shoot of <i>Aralia</i> elata SEEM: elatosides G, H, I, J. and K", <i>Chem Pharm Bull</i> , 43:1878-1882			
	50.	Yoshikawa et al., (1996) "Bioactive saponins and Glycosides. VI. Elatosides A and B, Potent Inhibitors of Ethanol Absorption, from the Bark of <i>Aralia elata</i> SEEM. (Araliaceae): The Structure-Requirement in Oleanolic Acid Glucuronide-Saponins for the Inhibitory Activity", <i>Chem. Pharm. Bull.</i> , 44:1915-1922			
	51.	Yoshikawa et al., (1996) "Bioactive saponins and glycosides. VII. On the hypoglycemic principles from the root cortex of <i>Aralia</i> elata Seem.: Structure related hypoglycemic activity of oleanolic acid oligoglycoside", <i>Chem Pharm Bull</i> , 44:1923-1927			
	52.	Yu et al., (1994) "Triterpenoid saponins from the roots of <i>Aralia</i> spinifolia", <i>J Nat Prod</i> , 57:978-982			
	53.	Zeng et al., (1994) "Chemical constituents of Aralia decaisneana Hance", Chung Kuo Chung Yao Tsa Chih, 19:550-551			
	54.	Zweytick et al., (2000) "Intracellular lipid particles of eukaryotic cells", <i>Biochemica et Biophysica Acta</i> , 1469:101-120			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

{W:\042	Date
1,	Considered
87\100	Considered

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.